Government-Owned Inventions; Availability for Licensing, 58265 [2018-25194]

Download as PDF Federal Register / Vol. 83, No. 223 / Monday, November 19, 2018 / Notices khammond on DSK30JT082PROD with NOTICES Podcasting website (https:// videocast.nih.gov). A portion of the National Cancer Advisory Board meeting will be closed to the public in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended, for the review, discussion, and evaluation of individual intramural programs and projects conducted by the National Cancer Institute, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Advisory Board, Ad Hoc Subcommittee on Global Cancer Research. Open: December 3, 2018, 5:30 p.m. to 7:00 p.m. Agenda: Discussion on Global Cancer Research. Place: Gaithersburg Marriott Washingtonian Center, 9751 Washington Boulevard, Gaithersburg, MD 20878. Contact Person: Dr. Robert T. Croyle, Acting Executive Secretary, NCAB Ad Hoc Subcommittee on Global Cancer Research, National Cancer Institute—Shady Grove, National Institutes of Health, 9609 Medical Center Drive, Room 4E420, Bethesda, MD 20892, (240) 276–6690, croyler@mail.nih.gov. Name of Committee: NCI Board of Scientific Advisors and National Cancer Advisory Board. Open: December 4, 2018, 8:45 a.m. to 4:15 p.m. Agenda: Joint meeting of the NCI Board of Scientific Advisors and National Cancer Advisory Board—NCI Director’s report, presentations, and review of concepts. Closed: December 4, 2018, 4:15 p.m. to 5:15 p.m. Agenda: Review of intramural program site visit outcomes and the discussion of confidential personnel issues. Place: National Cancer Institute—Shady Grove, 9609 Medical Center Drive, Room TE406 & 408, Rockville, MD 20850. Contact Person: Paulette S. Gray, Ph.D., Director, Division of Extramural Activities, National Cancer Institute—Shady Grove, National Institutes of Health, 9609 Medical Center Drive, Room 7W444, Bethesda, MD 20892, 240–276–6340, grayp@mail.nih.gov. Name of Committee: NCI Board of Scientific Advisors and National Cancer Advisory Board. Open: December 5, 2018, 9:00 a.m. to 12:45 p.m. Agenda: Joint meeting of the NCI Board of Scientific Advisors and National Cancer Advisory Board—Presentations and review of concepts. Place: National Cancer Institute—Shady Grove, 9609 Medical Center Drive, Room TE406 & 408, Rockville, MD 20850. Contact Person: Paulette S. Gray, Ph.D., Director, Division of Extramural Activities, National Cancer Institute—Shady Grove, National Institutes of Health, 9609 Medical VerDate Sep<11>2014 17:20 Nov 16, 2018 Jkt 247001 Center Drive, Room 7W444, Bethesda, MD 20892, 240–276–6340, grayp@mail.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. In the interest of security, NIH has instituted stringent procedures for entrance onto the NCI-Shady Grove campus. All visitors will be asked to show one form of identification (for example, a governmentissued photo ID, driver’s license, or passport) and to state the purpose of their visit. Information is also available on the Institute’s/Center’s home page: NCAB: https:// deainfo.nci.nih.gov/advisory/ncab/ncab.htm, BSA: https://deainfo.nci.nih.gov/advisory/ bsa/bsa.htm, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: November 14, 2018. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018–25193 Filed 11–16–18; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institutes of Health, HHS. ACTION: Notice. Frm 00044 Fmt 4703 Sickle Cell Anemia Treatment Through RIOK3 Inhibition Available for licensing and commercial development are methods for the treatment of beta-globinapathies such as sickle cell disease and betathalassemia by inhibiting the expression and/or activity of RIOK3 in erythroid cells such as primary erythroid progenitor cell or a CD34+ erythroid cells. RIOK3 inhibitors contemplated within the scope of the invention can be antibodies, siRNAs, microRNAs, antisense oligonucleotides or small molecules like Midostaurin, Axitinib, Bosutinib, or Ruxolitinib. Potential Commercial Applications: • Sickle cell disease • beta thalassemia Development Stage: • Early stage Inventors: Bjorg Gudmundsdottir, Laxminath Tumburu, John Tisdale (all of NHLBI) Intellectual Property: HHS Reference No. E–200–2018; U.S Provisional Patent Application 62/756,497 filed November 6, 2018. Licensing Contact: Michael Shmilovich, Esq, CLP; 301–435–5019; shmilovm@mail.nih.gov. Dated: November 7, 2018. Michael A. Shmilovich, Senior Licensing and Patenting Manager, National Heart, Lung, and Blood Institute, Office of Technology Transfer and Development. BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. to achieve expeditious commercialization of results of federally-funded research and development. FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained by emailing the indicated licensing contact at the National Heart, Lung, and Blood, Office of Technology Transfer and Development Office of Technology Transfer, 31 Center Drive, Room 4A29, MSC2479, Bethesda, MD 20892–2479; telephone: 301–402–5579. A signed Confidential Disclosure Agreement may be required to receive any unpublished information. SUMMARY: PO 00000 SUPPLEMENTARY INFORMATION: Technology description follows. [FR Doc. 2018–25194 Filed 11–16–18; 8:45 am] Government-Owned Inventions; Availability for Licensing AGENCY: 58265 Sfmt 4703 National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Division of Intramural Research Board of Scientific Counselors. The meeting will be closed to the public in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES, including consideration of personnel E:\FR\FM\19NON1.SGM 19NON1

Agencies

[Federal Register Volume 83, Number 223 (Monday, November 19, 2018)]
[Notices]
[Page 58265]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-25194]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. to achieve 
expeditious commercialization of results of federally-funded research 
and development.

FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained 
by emailing the indicated licensing contact at the National Heart, 
Lung, and Blood, Office of Technology Transfer and Development Office 
of Technology Transfer, 31 Center Drive, Room 4A29, MSC2479, Bethesda, 
MD 20892-2479; telephone: 301-402-5579. A signed Confidential 
Disclosure Agreement may be required to receive any unpublished 
information.

SUPPLEMENTARY INFORMATION: Technology description follows.

Sickle Cell Anemia Treatment Through RIOK3 Inhibition

    Available for licensing and commercial development are methods for 
the treatment of beta-globinapathies such as sickle cell disease and 
beta-thalassemia by inhibiting the expression and/or activity of RIOK3 
in erythroid cells such as primary erythroid progenitor cell or a CD34+ 
erythroid cells. RIOK3 inhibitors contemplated within the scope of the 
invention can be antibodies, siRNAs, microRNAs, antisense 
oligonucleotides or small molecules like Midostaurin, Axitinib, 
Bosutinib, or Ruxolitinib.

Potential Commercial Applications:

 Sickle cell disease
 beta thalassemia

Development Stage:

 Early stage
    Inventors: Bjorg Gudmundsdottir, Laxminath Tumburu, John Tisdale 
(all of NHLBI)
    Intellectual Property: HHS Reference No. E-200-2018; U.S 
Provisional Patent Application 62/756,497 filed November 6, 2018.
    Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019; 
[email protected].

    Dated: November 7, 2018.
Michael A. Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood 
Institute, Office of Technology Transfer and Development.
[FR Doc. 2018-25194 Filed 11-16-18; 8:45 am]
 BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.